axicabtagene ciloleucel -凯发k8娱乐app下载

axicabtagene ciloleucel -凯发k8娱乐app下载


axicabtagene ciloleucel - fosun kite's car-t cell therapy approved to be included in the 2022 version of shanghai “huhuibao”

(shanghai, china on may 25, 2022) on may 25, 2022, the 2022 version of shanghai’s urban customized commercial supplementary medical insurance “huhuibao” was officially launched for pre-sale. in this year, the premium is priced at rmb 129/year, with a total coverage of rmb 3.1 million, and the new version of “huhuibao” covers a wider range of participants and updated liability coverage. as china's first approved car-t cell therapy, axicabtagene ciloleucel, an innovator drug product manufactured by fosun kite (the joint venture of fosun pharma), was officially included in the 2022 version of shanghai "huhuibao", with a coverage period from may 25 to july 31, 2022.

axicabtagene ciloleucel is an autologous cd19-directed car-t cell therapy manufactured locally in shanghai and was approved for marketing in june 2021 for the treatment of adult patients with relapsed or refractory large b-cell lymphoma (r/r lbcl) after two or more lines of systemic therapy. as of may 25, 2022, axicabtagene ciloleucel has been listed in the urban huiminbao insurance initiatives in 32 provinces and municipalities and covered by more than 50 commercial insurances; and it has also been used by 81 therapeutic centers. among them, large claim amounts will be provided by beijing "jinghuibao", ningbo "tian yi yong ning bao" and hangzhou "west lake yilianbao" and other general insurances. axicabtagene ciloleucel has been officially included in the shanghai "huhuibao" this year. the insured will enjoy a 100% claim payment and a deductible of zero for car-t therapy regardless of their anamnesis, with a maximum coverage of rmb 500,000.

huang hai, ceo of fosun kite, says, "the inclusion of axicabtagene ciloleucel in the 2022 version of shanghai "huhuibao" is of great significance to clinicians and patients. this drug will benefit the vast number of patients with lymphomas and bring them new hopes ". as a representative of "innovator drug makers" in pudong during the epidemic, fosun kite continued its production in a closed manner in its shanghai production base during the epidemic, ensuring the continuous supply of car-t cell therapy. dedicated to the patient-centered and clinical demands-oriented principles, fosun kite will continuously improve its innovation capability to serve the chinese people for their health and benefits.


appendix: list of provinces and municipalities including axicabtagene ciloleucel in the list of special drugs for huiminbao as of may 25, 2022
1 changsha huiminbao
2 shanxi jinhuibao
3 suzhou suhuibao
4 hunan aiminbao
5 taiyuan wanhubao
6 beijing jinghuibao
7 hebei jihuibao
8 lanzhou jinchengbao
9 chongqing yukuaibao
10 hebei puhuibao
11 yanzhao jiankangbao
12 henan zhongyuan yihuibao
13 hangzhou west lake yilianbao
14 zhejiang wenzhou yikangbao
15 zhejiang ningbo tian yi yong ning bao
16 shandong yantai yanhuibao
17 shandong rizhao nuanxinbao
18 guangdong zhongshan xiangshanbao
19 chengdu huirongbao
20 sichuan suining huisuibao
21 guangdong province yunfu city huiyunbao
22 jiangsu changzhou changhuibao
23 hebei tangshan tanghuibao
24 shenzhen pengchengbao
25 shandong linyi linyibao
26 shandong liaocheng liaohuibao
27 sichuan dazhou dahuibao
28 guangxi nanning huiyongbao
29 shandong qingdao qindao e-bao
30 zhejiang jiaxing dabingwuyou
31 shanghai huhuibao
32 fujian ningde huiminbao

about fosun kite
as a joint venture of shanghai fosun pharmaceutical (group) co., ltd and u.s. kite pharma, fosun kite biotechnology co., ltd. (hereinafter referred as "fosun kite") is dedicated to the advancement of innovative cell therapy and its industrialization in china to benefit patients. headquartered in zhangjiang hi-tech park of shanghai, fosun kite has a 10,000 m2 car-t commercial manufacturing facility which has been completed and put into use in zhangjiang innovative medicine industry park. moreover, fosun kite has also built a 2,000 m2 r&d center with a professionally experienced r&d team, taking a combined approach of internal r&d effort and external partnering to build a sustainable pipeline including car-t programs in both early discovery and clinical stages.

for more information, please visit